Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis
Back

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Completed

Open to: ALL

Age: 18.0 - 65.0

Liverpool London Manchester

Medical Conditions

Dermatitis, Atopic
Dermatitis
Eczema

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2020 Apr 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention Arm Group : Part A: Intravenous UCB9741 arm 1;Part A: Intravenous UCB9741 arm 2;Part A: Intravenous UCB9741 arm 3;Part A: Intravenous UCB9741 arm 4;Part A: Intravenous UCB9741 arm 5;Part A: Subcutaneous UCB9741 arm 1;Part A: Subcutaneous UCB9741 arm 2;Part B: Intravenous UCB9741 arm;

Intervention Type : DRUG
Intervention Description : - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

Intervention Arm Group : Part A: Intravenous Placebo arm;Part B: Intravenous Placebo arm;

Intervention Type : DRUG
Intervention Description : Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.

Intervention Arm Group : Part A: Subcutaneous Placebo arm;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Up0089 104
    Liverpool
  • Up0089 101
    London
  • Up0089 103
    Manchester


The study is sponsored by UCB Biopharma SRL



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04643457
Last updated 03 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top